Skip to main content

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion Master

Clinical Trial Grant
Duke Scholars

Awarded By

Amgen, Inc.

Start Date

January 27, 2025

End Date

January 14, 2030
 

Awarded By

Amgen, Inc.

Start Date

January 27, 2025

End Date

January 14, 2030